scholarly journals One-year follow-up of treatment outcomes and patient opinions of Retraining and Control Therapy (ReACT) for pediatric functional seizures

2021 ◽  
pp. 100503
Author(s):  
Lindsay Stager ◽  
Jerzy P. Szaflarski ◽  
Aaron D. Fobian
Keyword(s):  
Treatment Outcomes ◽  
Control Therapy ◽  
One Year ◽  
And Control

scholarly journals Catastrophic costs due to tuberculosis worsen treatment outcomes: a prospective cohort study in Indonesia

2020 ◽  
Vol 114 (9) ◽  
pp. 666-673
Author(s):  
Ahmad Fuady ◽  
Tanja A J Houweling ◽  
Muchtaruddin Mansyur ◽  
Erlina Burhan ◽  
Jan Hendrik Richardus
Keyword(s):  
Treatment Outcomes ◽  
Treatment Adherence ◽  
Mixed Models ◽  
Multivariable Analysis ◽  
Annual Household Income ◽  
Rural Districts ◽  
Tb Treatment ◽  
Unsuccessful Treatment ◽  
One Year

Abstract Background While the incidence of catastrophic costs due to tuberculosis (TB) remains high, there is little evidence about their impact on TB treatment outcomes and adherence. We assessed their effect on treatment outcomes and adherence in Indonesia. Methods We interviewed 282 adult TB patients who underwent TB treatment in urban, suburban and rural districts of Indonesia. One year after the interview, we followed up treatment adherence and outcomes. We applied multivariable analysis using generalized linear mixed models. Results Follow-up was complete for 252/282 patients. Eighteen (7%) patients had unsuccessful treatment and 40 (16%) had poor adherence. At a threshold of 30% of annual household income, catastrophic costs negatively impacted treatment outcomes (adjusted odds ratio [aOR] 4.15 [95% confidence interval {CI} 1.15 to 15.01]). At other thresholds, the associations showed a similar pattern but were not statistically significant. The association between catastrophic costs and treatment adherence is complex because of reverse causation. After adjustment, catastrophic costs negatively affected treatment adherence at the 10% and 15% thresholds (aOR 2.11 [95% CI 0.97 to 4.59], p = 0.059 and aOR 2.06 [95% CI 0.95 to 4.46], p = 0.07). There was no evidence of such an effect at other thresholds. Conclusions Catastrophic costs negatively affect TB treatment outcomes and treatment adherence. To eliminate TB, it is essential to mitigate catastrophic costs.

Treatment Outcomes in the Tube Versus Trabeculectomy Study After One Year of Follow-up

2007 ◽  
Vol 143 (1) ◽  
pp. 9-22.e2 ◽  
Author(s):  
Steven J. Gedde ◽  
Joyce C. Schiffman ◽  
William J. Feuer ◽  
Leon W. Herndon ◽  
James D. Brandt ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
One Year ◽  
Tube Versus

Young systemic lupus erythematosus patients with no hearing involvement: 10-year follow up

2012 ◽  
Vol 127 (1) ◽  
pp. 38-42 ◽  
Author(s):  
J R García-Berrocal ◽  
B De Diego ◽  
A Roldán-Fidalgo ◽  
M Yebra-Bango ◽  
I Millán ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Hearing Loss ◽  
Lupus Erythematosus ◽  
Normal Hearing ◽  
Systemic Lupus ◽  
Progressive Hearing Loss ◽  
The Mean ◽  
One Year ◽  
And Control

AbstractObjective:To evaluate patients with systemic lupus erythematosus and normal hearing over 10 years, compared with healthy controls.Methods:Thirty patients diagnosed with systemic lupus erythematosus were evaluated in a prospective, descriptive study. Eight patients fulfilled the inclusion criteria, i.e. normal otoscopy, normal hearing, normal imaging and disease duration of less than one year. Eleven healthy companions of ENT patients were recruited as controls.Results:At study commencement, the mean patient age was 32.75 years (range, 15–49 years) and there were no statistically significant audiometric differences between patients and controls. No statistically significant audiometric changes were found either within or between the patient and control groups at 10-year follow up.Conclusion:These results supply no evidence for progressive hearing loss in systemic lupus erythematosus patients with no hearing involvement at study commencement. Therefore, we recommend audiometric tests only for systemic lupus erythematosus patients complaining of hearing loss, or for other clinical purposes. It is conceivable that asymptomatic hearing loss could be observed over a more extended follow-up period (i.e. more than 10 years).

Reduced fluence corneal cross-linking in mild to moderate keratoconus: One year-follow-up

2020 ◽  
pp. 112067212096656
Author(s):  
Seyed Reza Ghaffari ◽  
Saeed Khaheshi ◽  
Fateme Alipour ◽  
Somayye Mashhadi Farahani ◽  
Amir-Hooshang Beheshtnejad ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Eligible Patient ◽  
Case Series ◽  
Control Group ◽  
Data Analyst ◽  
Cell Counts ◽  
Group 2 ◽  
One Year ◽  
And Control

Purpose: To evaluate the safety and efficacy of reduced fluence CXL (lower dose of UV-A irradiation) in mild to moderate keratoconus. Setting: Farabi Eye Hospital, Tehran, Iran. Design: Non-randomized prospective comparative interventional case series. Every eligible patient included in the study (mild to moderate progressive keratoconus) was randomly allocated to case (reduced fluence) and control (standard) groups, except for bilateral patients. In these patients the eye with more advanced disease was allocated to control group and the other eye was randomly assigned in either case or control group. Operators performing refraction and images and the data analyst were masked, but patients and physicians were not. Methods: Forty-six eyes of 38 patients were recruited. Group 1 received 7 min (fluence of 3.8 J/cm2), while group 2 received 10 min of 9 mW/cm2 UV-A (fluence of 5.4 J/cm2). Visual, keratometric and biomechanical outcomes were compared between groups. Results: At last follow-up (mean12 months, range 6–24 months), there were no statistically significant differences in changes in uncorrected visual acuity, best corrected distance visual acuity, Kmax, Kmean, corneal hysteresis, corneal resistance factor, endothelial cell counts, demarcation line depth, and intraoperative pain scores between groups (all p-values < 0.05). Conclusion: The results of this study show comparable one-year outcomes between 3.8 and 5.4 J/cm2 accelerated CXL in mild to moderate keratoconus. Should the results of this study be confirmed in longer follow-ups, using a reduced fluence setting could be considered as an alternative to standard treatment in these patients.

Use of Quality-Adjusted Tooth Years as an Outcome Measure of Periodontal Treatment: A Quasi Experimental Study

2020 ◽  
pp. 232020682097599
Author(s):  
Tuti Ningseh Mohd-Dom ◽  
Sharifa Ezat Wan Puteh ◽  
Rasidah Ayob ◽  
Marc Tennant ◽  
Syed Mohamed Aljunid
Keyword(s):  
Treatment Outcomes ◽  
Health Impact ◽  
Periodontal Treatment ◽  
Life Years ◽  
Quasi Experimental ◽  
Estimate Quality ◽  
One Year ◽  
Attachment Level

Aim: To develop a simple approach to estimate quality-adjusted tooth years of teeth (QATY) treated for periodontitis and determine gains in QATY after undergoing cause-related periodontal therapy (CRPT). Quality-adjusted life years (QALY) gained for these patients were also determined. Materials and Methods: Patients newly diagnosed with periodontitis ( n = 165, 58.8% females, mean age 43.3 years) were recruited from periodontal specialist clinics. They received CRPT within a period of one year. We used the EuroQoL 5 Dimension (EQ-5D) and the Malaysian Oral Health Impact Profile (OHIP-14) indexes to measure changes in quality-of-life after one year of periodontal treatment. We then used these two scores to calculate their respective utilities and subsequently calculated QALY and QATY. Results: Proportions of deep periodontal sites (≥ 4 mm) decreased from 32.7% to 23.2% and patients gained an average of 0.3 mm of clinical attachment level per tooth at post-treatment follow-up. Improvements in means of OHIP-14 scores from 20.30 to 12.7 were consistent with changes in EQ-5D utilities from 0.81 to 0.91. Treated teeth gained 20.4 years for longevity while patients gained 17 QATYs. This is in line with the increase of 3.8 QALYs. Both treatment outcomes and clinical parameters were statistically significant at P < .0001. Conclusions: The method of estimating QATY using utilities derived from OHIP-14 combined with tooth life expectancy demonstrated that it may be used to measure effective treatment outcomes and is found to be consistent with improvements in QALY scores as calculated using EQ-5D-3L.

Favoring Trauma as an Etiological Factor in Denture Stomatitis

2008 ◽  
Vol 87 (5) ◽  
pp. 440-444 ◽  
Author(s):  
E. Emami ◽  
P. de Grandmont ◽  
P.H. Rompré ◽  
J. Barbeau ◽  
S. Pan ◽  
...  
Keyword(s):  
Etiological Factor ◽  
Odds Ratios ◽  
Denture Stomatitis ◽  
Exact Test ◽  
Fisher's Exact Test ◽  
Fisher’S Exact Test ◽  
One Year ◽  
And Control

The etiology of denture stomatitis remains controversial. Trauma due to unstable dentures has been suggested as an etiological factor. Therefore, we tested the hypothesis that the prevalence of denture stomatitis is reduced when mandibular dentures are stabilized by implants. Data were collected at a one-year follow-up from 173 edentulous elders who had randomly received mandibular implant overdentures or conventional dentures. The diagnosis of denture stomatitis was determined according to the Newton classification. Elders wearing conventional dentures were almost 5 times more likely to have denture stomatitis than those wearing mandibular two-implant overdentures ( P < 0.0001, Fisher’s exact test). Adjusted odds ratios showed that only the type of the prosthesis (AOR = 4.54, 95% CI 2.20 to 9.40) and nocturnal wear (AOR = 3.03, 95% CI 1.24 to 7.40) predict the frequency of denture stomatitis. Thus, implant overdentures may reduce oral mucosal trauma and control denture stomatitis.

scholarly journals Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model

2021 ◽  
pp. 2003492
Author(s):  
Jan Heyckendorf ◽  
Sebastian Marwitz ◽  
Maja Reimann ◽  
Korkut Avsar ◽  
Andrew DiNardo ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Whole Blood ◽  
Learning Algorithm ◽  
Multidrug Resistant ◽  
World Health ◽  
End Of Treatment ◽  
One Year ◽  
Health Organization ◽  
Therapy Treatment

BackgroundThe World Health Organization recommends standardised treatment durations for patients with tuberculosis. We identified and validated a host-RNA signature as a biomarker for individualised therapy durations for patients with drug-susceptible (DS)- and multidrug-resistant (MDR)-tuberculosis.MethodsAdult patients with pulmonary tuberculosis were prospectively enrolled into 5 independent cohorts in Germany and Romania. Clinical and microbiological data, and whole-blood for RNA transcriptomic analysis were collected at pre-defined timepoints throughout therapy. Treatment outcomes were ascertained Treatment outcomes were ascertained by TBNET criteria (6-month culture status/one-year follow-up). A whole-blood RNA therapy end model was developed in a multi-step process involving a machine-learning algorithm to identify hypothetical individual end-of-treatment timepoints.ResultsFifty patients with drug-susceptible (DS)-tuberculosis and 30 patients with MDR-tuberculosis were recruited in the German identification cohorts (DS- and MDR-GIC), 28 patients with DS-tuberculosis and 32 patients with MDR-tuberculosis in the German validation cohorts (DS- and MDR-GVC), and 52 patients with MDR-tuberculosis in the Romanian validation cohort (MDR-RVC). A 22-gene RNA model that defined cure-associated end-of-therapy timepoints was derived from the DS- and MDR-GIC data. The model was superior to other published signatures to accurately predict clinical outcomes for patients in the DS-GVC (AUC=0.94 [95%CI:0.9–0.98]) and suggests that cure may be achieved with shorter treatment durations for tuberculosis patients in the MDR-GIC (mean reduction 218.0 days, 34.2%, p<0.001), the MDR-GVC (mean reduction 211.0 days, 32.9%, p<0.001), and the MDR-RVC (mean reduction of 161.0 days, 23.4%, p=0.001).ConclusionBiomarker-guided management may substantially shorten the duration of therapy for many patients with MDR-tuberculosis.

Sign in / Sign up

Export Citation Format

Share Document